medigraphic.com

2001, Number 4

<< Back

Rev Mex Anest 2001; 24 (4)

Etofenamato: Características farmacologícas y clinicas de la formulación intramuscular

Herrera GL, Guevara LU, Torres GRA

Language: Spanish
References: 45
Page:
PDF size: 461.94 Kb.


ABSTRACT

Etofenamate is a flufenamic acid-derived compound, belonging to the compounds derived from the anthranilic acid. This compound was originally used as a formulation for oral route administration, and later on as cream or gel for topical use. However, the pharmacological characteristics were improved by combining middle-chain triglycerides, leading to a compound for i.v. administration which improved the therapeutical profile of this non-steroidal antiinflammatory drug, being outstanding not only for inhibiting the cyclooxygenase route but, in a parallel way, for inhibiting also the lipooxygenase route. The physical-chemical, pharmacological and clinical characteristics are revised in this document.


REFERENCES

  1. DELL HD., FIELDLER J., JACOBI H., WAESCHE B. -On biochemistry and pharmacokinetics of etofenamate/Studies in man. -Arzneim-Forsch/Drug Res 1977; 27 (1), 6b:1322-5.

  2. DELL HD., BECKERMANN B., FIEDLER J., AND KAMP R.. -Renal elimination and metabolism of etofenamate after intramuscular administration of diferent doses to volunteers. -Arzneim-Forsch/Drug Res 1990; 40 (3):311-6.

  3. DELL HD., JACOBI H., WEASCHE B. -Biochemical studies on etofenamate. Experimental tests in animals. -Arzneim-Forsch/Drug Res 1977; 27 (6b):1316-21.

  4. PELSTER B., DELL HD. -Antiphlogistic and analgesic activity of etofenamate in laboratory animals after intramuscular administration. -Arzneim-Forsch/Drug Res 1990; 40 (3):297-300.

  5. JACOBI H., BREIER P., DELL HD., AND LORENZ D. - Pharmacology and toxicology of etofenamate 1st communication. -Arzneim-Forsch/Drug Res 1977; 27 (I) 6b:1326-33.

  6. JACOBI H., DELL HD., AND LORENZ D. -Pharmacology and toxicology of etofenamate 2nd communication. -Arzneim-Forsch/Drug Res 1977; 27(I) 6b:1333-40.

  7. Prolongation of the antiphlogistic/analgesic efficacy by intramusculary injected etofenamate. -2 nd world conference on inflammation antirheumatics, analgesics, inmunomodulators. Monte Carlo March 19-22 1986:A-115

  8. DELL HD., BECKERMANN B., KAMP R. -Pharmacokinetics and tolerability of etofenamate I.M. compared with I.M. NSAIDS in aquous solutions. -2 nd world conference on inflammation antirheumatics, analgesics, inmunomodulators. Monte Carlo March 19-22 1986;A-186.

  9. DELL HD., BRONS J., FIEDLER J., KAMP R., PELSTER B. -Animal experimental evidence of long-lasting liberation of etofenamate by half-life prolongation after intramuscular application. -Arzneim-Forsch/Drug Res 1990; 40 (3):300-5.

  10. BECKERMANN B., BOCK E., KAMP R., DELL HD. -Plasma level studies on volunteers after intramuscular application of different doses of etofenamate in oily solution. -Arzneim-Forsch/Drug Res 1990; 40 (3):305-11.

  11. GUYON B., ORY JP., DELACOUR JL., WAGSCHAL G., DAOUDAL P. -Renal Complications of Non-Steroid Anti-Inflammatory drugs. -Rev. Med. Interne 1983; 4 (2):189-198.

  12. BECKERMANN B., DELL HD., KAMP R. -Pharmacokinetics of etofenamate in oily solution, a new delivery system for I.M. application with prolonged drug liberation. -2 nd world conference on inflammation antirheumatics, analgesics, inmunomodulators. Monte Carlo March 19-22 1986; A-185

  13. KOEHLER G., TRESSEL W., DELL HD., LANGER M., WIRZBACH E. -Plasma, synovia, and tissue pharmacokinetics of etofenamate/ flufenamic acid in patients with rheumatoid arthritis after single administration of Rhemon I.M. -Hungarian Rheumatology 1991; 32(Suppl):P4-311.(Abstract of the XIIth European Congress of Rheumatology June 30–July 6).

  14. KOEHLER G., TRESSEL W., DELL HD., DOERSING M., et al. -Pharmacokinetic of etofenamte and flufenamic acid in plasma, synovia and tissues of patients with chronic polyarthritis after application of oily etofenamate solution. -Arzneim-Forsch/Drug Res 1992; 42 (12):1487-1491.

  15. KOEHLER G., DELL HD. -Pharmacokinetics and biochemical characteristics of etofenamate I.M. in patients with chronic polyarthritis. -Z Rheumatol 1986; 45 (4):185.

  16. BECKERMANN B., BOCK E., DELL HD., KOEHLER G., SEITZ I. -Study of the age and sex dependence of the pharmacokinetics of I.M. administered etofenamate. -Rheuma Schmerz Entzuendung 1991; 11 (2):3-14.

  17. DELL HD., FIEDLER J. -Elimination of etofenamate into milk. -Arch Pharm 1983; 316 (9):746-751.

  18. NIETSCH P. -Therapy with etofenamate I.M. -Kassernartz Verlag 1991.

  19. KRETZCHMAR. A. -Acemetacin and etofenamate. Drugs to keep your patients on the move. -A Satellite Symposium carried out on the ocassion of the XIXth ILAR Congress of Rheumatology organized by Troponwerke, Cologne, Germany in Singapore on June 9, 1997; 1-9.

  20. JACOBI H., BREIER P., DELL HD. -Pharmacology and Toxicology of Etofenamato 3rd Communication. -Arzneim-Forsch/Drug Res 1977; 27 (6b):1340–1349.

  21. ROBERT AL., FRANK KA., SOBERMAN RJ. -Leukotrienes and other products of the lipoxygenase pathway. -N Eng J Med 1990; 323 (10):645-55.

  22. BRAY MA. -Leukotrienes in Imflammation. -Agents Actions 1986; 19 (1-2):87–89.

  23. FRUCHTMANN R., KRUPKA U., PELSTER B. -Inhibition of lipoxygenase and cicloxygenase pathway of the arachidonic acid metabolism by etofenamate. -Akt Rheumatol 1984; 9:165-68.

  24. FRUCHTMANN R., KRUPKA U., PELSTER B. -Effects of anti-inflammatory drugs on the arachidonic acid metabolism. -III. Intern. Congress of Inflammation, Paris 1984; 3-7. Sept.

  25. KANKAANRANTA H., MOILANEN E. -Flufenamic and tolfenamic acids inhibit calcium influx in human polymorphonuclear leukocytes. -Molecular Pharmacology 1995; 47 (5):1006-13.

  26. KANKAANRANTA H., MOILANEN E. -Fenamates inhibit calcium entry in human neutrophils. -Scand J Rheumatol 1995 24 (3):191 Molecular Pharmacology 1995; 47 (5):1006-13.

  27. KANKAANRANTA H., LUOMALA M., KOSONEN O., MOILANEN E. Inhibition by fenamates of calcium influx and proliferation of human lymphocytes. -British Journal of Pharmacology 1996; 119:487-494.

  28. OHLROGGE R., PELSTER B., BERNARD I. -Efficacy and tissue-tolerability of etofenamate after I.M. injection. -Hungarian Rheumatology 1991; 32 (Suppl):4–312. (Abstract of the XIIth European Congress of Rheumatology June 30–July 6).

  29. PELSTER B. -Etofenamate in oily solution: new facilities for treatment of severe inflammation pain. -Br J Rheumatol; 1992; 31 (Suppl 2):157.

  30. FRICKE R., TAGHAWINEJAD M. -Nonsteroidal Antirheumatic drugs I.M. for treatment of secundary inflammatory reactions after chemical synovectomy with sodium morhulat. -EULAR Symposium Wien. 1985 9-12. Oct.

  31. PELSTER B. -Treatment of rheumatic diseases with etofenamate I.M., an injectable depot NSAID. -Rheumatol Eur 1996; 25 (Suppl 1):128.

  32. LEEB B., DELL HD. -Plasma and synovial fluid concentrations of etofenamate and flufenamic acid after multiple intramuscular injection of Rheumon R Depot in patientes with rheumatoid arthritis. -Hungarian Rheumatology 1991; 32 (Suppl):P4-310. (Abstract of the XIIth European Congress of Rheumatology June 30–July 6).

  33. PELSTER B. -Acute treatment of rheumatic diseases. Etofenamte I.M. as a short-term therapy. -Zeitschrift für Allgemeinmedizin 1993; 69 (16):440–4.

  34. FROMME K., KULLICH W., KLEIN G. -Parenteral use of etofenamte in lumbar syndromes. -Therapiewoche 1989; 4 (6):549–51

  35. MEYER-OVEN M., BENEKE M., BLUMBERGER W. -Onset of action and efficacy of etofenamte and diclofenac injectable solutions. -Hungarian Rheumatology 1991; 32 (Suppl):P4-314. (Abstract of the XIIth European Congress of Rheumatology June 30–July 6).

  36. STRATZ TH. -A comparison of etofenamate I.M. and diclofenac sodium I.M. in the treatment of acute lumbago. -Fortschr Med 1990; 108 (13):66–70.

  37. MIELKHE K. -Injection treatment of acute lumbal syndrome: comparison of etofenamate to diclofenac. -Therapiewoche 1990; 40 (7):462–5.

  38. SOUSA-MARQUEZ MJ. -Etofenamate in the treatment of renal colic. -Acta Urol Port 1996; 13 (1–4):43–6.

  39. PELSTER B., KOEHLER G., TRESSEL W. -Postoperative pain control by preoperative I.M. injection of etofenamate. -Poster XIII European Congress of Rheumatology, 18–23 June, 1995, Amsterdam, The Netherlands: 1995.

  40. PELSTER B., KOEHLER G., TRESSEL W. -Postoperatiove pain control by preoperative I.M. injection of etofenamate. -Rheumatol Europe 1995; 24 (Suppl 3) A-D235:287.

  41. PELSTER B., KOEHLER G., TRESSEL W. -Postoperatiove pain control by preoperatrive I.M. injection of etofenamate. -Topics Arthritis Rheum 1995; (2) 1-4.

  42. HOLZGREVE., STEDTFELD HW. -Postoperative therapy for pain and swelling: A double-blind study of I.M. etofenamate in comparison with a morphine derivate. -Medizinische Welt 1990; 41 (2):198–201.

  43. NIETSCH P. -Side effects and interactions during therapy with non-steroidal antirheumatics agents. -Medizinische Welt 1986; 37 (4):18–21.

  44. LEWIS JH. -Hepatic Toxicity of non-steroideal anti-inflammatory drugs. -Clin Pharm 1984; 3 (2):128-138

  45. DELL HD., BECKERMANN B., SEITZ J. -The advantages of oil-based intramuscular preparations of NSAIDS. -Therapiewoche 1991; 41 (43):2798–2803.




2020     |     www.medigraphic.com